India’s Centre Seeks NPPA Report on Steep Hospital Consumable Markups After 2,841% Pricing Gap Found

India’s central government has asked the National Pharmaceutical Pricing Authority to assess unusually steep markups on hospital consumables, after Maharashtra’s drug regulator flagged massive gaps between what hospitals pay for items like IV sets and catheters and what they charge patients. The request, reported Wednesday, could revive trade-margin caps and extend price regulation to a wide category of medical consumables that currently fall largely outside India’s pricing controls.

What the Maharashtra Survey Found

The review traces back to a survey conducted by the Maharashtra State Price Monitoring Resource Unit, which compared hospital procurement prices for common inpatient items against the maximum retail prices, or the amounts actually billed to patients. The gaps were stark. An IV infusion set procured for ₹11.05 was billed to patients at an MRP of ₹325, a markup of roughly 2,841 percent. A 10 ml syringe purchased for ₹6.75 was sold for ₹57.20, a 747 percent markup. A catheter bought for ₹29.41 carried an MRP of ₹310. An IV cannula priced at ₹22.50 was sold for ₹424, nearly 19 times its procurement cost, and a nebulizer mask costing ₹40 was billed at ₹715, a markup of 1,687 percent.

Tukaram Mundhe, Commissioner of the Maharashtra Food and Drugs Administration, who first sought the central review, has framed the findings as more than a pricing anomaly. According to Mundhe, these discrepancies raise genuine patient-protection concerns, since patients typically have no way to know whether the price of a device or consumable used in their treatment is remotely fair.

Why the Centre Is Stepping In

The Maharashtra findings didn’t emerge in isolation. Drug-control authorities in Punjab, Rajasthan, and Tamil Nadu have separately submitted similar representations flagging comparable pricing gaps in their own states, giving the Centre’s request to the NPPA a multi-state pattern to work from rather than a single regional anomaly. NPPA officials are now comparing manufacturer filings and internal company price lists against the Maharashtra survey data as part of the assessment.

How India’s Current Price Control System Works, and Where It Falls Short

The gap the Maharashtra survey exposed traces back to a structural feature of India’s pricing framework. Under the Drugs (Prices Control) Order, 2013, the NPPA sets ceiling prices only for “scheduled formulations” and a specific list of medical devices it has chosen to regulate directly, categories like coronary stents and knee implants, where the authority has previously imposed price caps as steep as 85 and 70 percent respectively.

Everything outside that scheduled list falls under a much looser rule known as Paragraph 20, which limits annual MRP increases to 10 percent but sets no uniform ceiling price across a device category in the first place. That distinction matters enormously in practice: a 10 percent annual cap does nothing to correct a markup that was already 2,000 or 2,800 percent to begin with, it simply limits how much further an already-inflated price can climb each year. Items like IV sets, syringes, and catheters have historically sat in this loosely regulated Paragraph 20 category, which is precisely why the markups the Maharashtra survey uncovered were legally possible in the first place.

This Isn’t a New Problem

The pattern Maharashtra’s survey uncovered is strikingly similar to findings the NPPA itself documented nearly a decade ago. In an earlier review of billing at four major private hospitals in Delhi, the NPPA found that medicines, consumables, and diagnostics together made up roughly 55 percent of total billed amounts, far outweighing room rent and procedural charges combined. That study found an IV set purchased by a hospital for roughly ₹8.39 being billed to patients at ₹115, a margin of more than 2,100 percent, a gap that closely mirrors what Maharashtra’s regulators found on the same category of product years later. The NPPA at the time described the pattern bluntly as unethical profiteering in a failed market system.

That earlier study never led to a uniform price cap on hospital consumables broadly, which is part of why today’s Maharashtra findings look so familiar: the underlying structural loophole, unregulated non-scheduled consumables sold at whatever markup the market will bear, was never closed.

What Could Happen Next

According to reporting on the Centre’s request, the NPPA review could lead to reviving trade-margin caps, a mechanism the authority has used before to limit the percentage markup allowed between a product’s price to the distributor and its final price to the patient, rather than fixing an absolute ceiling price. It could also extend formal price scrutiny to hospital consumables that currently sit entirely outside the scheduled device list. Either outcome would track closely with recommendations a parliamentary committee made earlier this year, when it found that even after the NPPA’s earlier stent and implant price cuts, overall patient costs barely moved because unregulated procedural and consumable charges absorbed the savings, a gap this Maharashtra-triggered review appears aimed at closing directly.

What’s at Stake for Patients

For now, the NPPA’s terms of reference, the specific product categories it will examine, and its timeline for completing the assessment remain unclear. What is clear is the underlying incentive structure this review is meant to address: as long as everyday hospital consumables remain outside meaningful price regulation, the substantial savings India has already achieved on higher-profile items like cardiac stents and knee implants can continue to be quietly offset by markups on the syringes, IV sets, and catheters bundled into nearly every hospital stay.